SCHEMBL7040353

SCHEMBL7040353

COc1ccc(C(N)Cc2ccccc2)c(OC)c1

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.49
CYP2D6 P10635 1/20 0.49
CYP2C19 P33261 1/20 0.49
TAAR1 Q96RJ0 2/20 0.47
HTR2A P28223 1/20 0.45
ALDH1A1 P00352 3/20 0.44
ADRB3 P13945 1/20 0.44
MAPT P10636 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
TSHR P16473 1/20 0.44
CAPN1 P07384 1/20 0.44
MAPK1 P28482 1/20 0.44
PTK2B Q14289 1/20 0.44
POLB P06746 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
SLC6A4 P31645 1/20 0.44
ALOX15 P16050 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3285266 0.84 CYP2D6 (0.51) CYP1A2CYP2D6CYP2C19TAAR1HTR2A
SCHEMBL15490529 0.79 CA12 (0.48) CYP1A2CYP2D6HTR2AALDH1A1MAPT
SCHEMBL11658602 0.79 ADRA1A (0.56) CYP1A2CYP2D6TAAR1HTR2AALDH1A1
SCHEMBL8784289 0.78 LDHA (0.50) CYP1A2CYP2D6CYP2C19SLC6A4
SCHEMBL789023 0.78 CA12 (0.47) CYP1A2CYP2D6TAAR1HTR2AALDH1A1
SCHEMBL790317 0.78 CA12 (0.47) CYP1A2CYP2D6TAAR1HTR2AALDH1A1
SCHEMBL414370 0.76 MEN1 (0.48) CYP1A2CYP2D6ALDH1A1MAPTMAPK1
SCHEMBL806607 0.76 CA12 (0.46) CYP1A2CYP2D6TAAR1HTR2AALDH1A1
SCHEMBL6761354 0.76 HSD17B10 (0.49) CYP2D6ALDH1A1MAPK1
SCHEMBL6761350 0.76 HSD17B10 (0.49) CYP2D6ALDH1A1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0659737-B1 Catecholamine surrogates useful as beta 3 agonists BRISTOL MYERS SQUIBB CO (US) 2003-03-26 EP disclosed
US-5776983-A ANTIDIABETIC AGENTS, OBESITY, GASTROINTESTINAL DISORDERS BRISTOL-MYERS SQUIBB COMPANY (US) 1998-07-07 US disclosed
EP-0659737-A2 Catecholamine surrogates useful as B3 agonists BRISTOL-MYERS SQUIBB COMPANY (US) 1995-06-28 EP disclosed